Meiji Yasuda Asset Management Co Ltd. Invests $1.83 Million in Solventum Corporation $SOLV

Meiji Yasuda Asset Management Co Ltd. purchased a new position in Solventum Corporation (NYSE:SOLV) during the 3rd quarter, HoldingsChannel reports. The firm purchased 25,052 shares of the company’s stock, valued at approximately $1,829,000.

A number of other institutional investors have also recently added to or reduced their stakes in SOLV. Deseret Mutual Benefit Administrators increased its position in Solventum by 78.7% in the third quarter. Deseret Mutual Benefit Administrators now owns 370 shares of the company’s stock worth $27,000 after buying an additional 163 shares during the period. CYBER HORNET ETFs LLC bought a new position in shares of Solventum during the second quarter worth about $28,000. MUFG Securities EMEA plc bought a new position in shares of Solventum during the second quarter worth about $31,000. State of Wyoming acquired a new stake in shares of Solventum in the 2nd quarter worth about $33,000. Finally, MTM Investment Management LLC bought a new stake in Solventum in the 2nd quarter valued at about $40,000.

Solventum Stock Down 2.1%

Solventum stock opened at $69.30 on Monday. Solventum Corporation has a 52 week low of $60.70 and a 52 week high of $88.20. The stock has a market cap of $12.02 billion, a price-to-earnings ratio of 7.81, a PEG ratio of 1.14 and a beta of 0.40. The company’s 50-day moving average price is $77.62 and its two-hundred day moving average price is $76.20. The company has a current ratio of 1.23, a quick ratio of 0.89 and a debt-to-equity ratio of 1.00.

Solventum (NYSE:SOLV) last issued its quarterly earnings results on Thursday, February 26th. The company reported $1.57 earnings per share for the quarter, topping analysts’ consensus estimates of $1.50 by $0.07. The company had revenue of $2 billion during the quarter, compared to analyst estimates of $1.96 billion. Solventum had a net margin of 18.69% and a return on equity of 25.26%. The business’s revenue for the quarter was down 3.7% compared to the same quarter last year. During the same period in the prior year, the business posted $1.41 EPS. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. On average, analysts expect that Solventum Corporation will post 6.58 EPS for the current fiscal year.

Solventum declared that its Board of Directors has initiated a stock repurchase plan on Thursday, November 20th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the company to purchase up to 7.5% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s board believes its shares are undervalued.

Analysts Set New Price Targets

A number of research firms have issued reports on SOLV. Weiss Ratings reissued a “hold (c)” rating on shares of Solventum in a research note on Tuesday, January 27th. Stifel Nicolaus lifted their price target on Solventum from $88.00 to $105.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. Wall Street Zen downgraded Solventum from a “buy” rating to a “hold” rating in a research report on Sunday. BTIG Research reissued a “buy” rating and issued a $100.00 price objective on shares of Solventum in a report on Friday, February 27th. Finally, Wells Fargo & Company lowered their target price on Solventum from $86.00 to $83.00 and set an “equal weight” rating on the stock in a research report on Friday, February 27th. Seven investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, Solventum currently has an average rating of “Moderate Buy” and a consensus target price of $93.70.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.